Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?

The phase 3 RASolute 302 trial demonstrated significant overall and progression-free survival benefits with daraxonrasib over investigator's choice chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma harboring RAS G12 mutations after progression on prior chemotherapy.1 The benefit in patients with non-G12 RAS mutations or RAS wild-type tumors remains unclear.